Axial spondyloarthritis (axSpA) places significant burden on patients across the spectrum of axSpA (non-radiographic axSpA [nr-axSpA] and ankylosing spondylitis [AS]).1

Patients with nr-axSpA may suffer from night-time back pain and morning stiffness, but don’t always tell their healthcare professional. This may be especially true in patients whose stiffness resolves with movement.2

Both nr-axSpA and AS have a similar symptom burden:1

Handrawn image of man icon displaying pain

Pain

Handrawn image of person icon displaying fatigue

Fatigue

Handrawn image of person icon displaying functional impairment

Functional impairment

Handrawn image of briefcase icon displaying lost work time

Lost work time

Handrawn image of person icon sitting on bed

Reduced activity

 

 

 

Similarities3

Image of handrawn orange underline rule

Clinical presentation

Level of pain

Decease in functional abilities

Decrease in HRQoL*

Patient global assessment of disease

Differences

Image of handrawn orange underline rule

Radiographic damage in AS3

Reduced spinal mobility in AS4

More women with nr-axSpA5

More men with AS (ratio 2:1 vs women)5

 

 

Image of blue arrow with link to Disease identification

 

*As measured by SF-36 and ASQoL questionnaires.3

AS, ankylosing spondylitis; ASQoL, Ankylosing Spondylitis Quality of Life; axSpA, axial spondyloarthritis; HRQoL, health-related quality of life; nr-axSpA, non-radiographic axial spondyloarthritis; SF-36, Short Form 36 Health Survey.

References:

  1. Mease PJ, et al. Arthritis Care Res (Hoboken). 2018;70(11):1661–1670.
  2. Strand V & Singh JA. Mayo Clin Proc. 2017;92(4):555–564.
  3. Kiltz U, et al. Arthritis Care Res (Hoboken). 2012;64(9):1415–1422.
  4. Malaviya AN, et al. Int J Rheum Dis. 2015;18(7):736–741.
  5. Boonen A, et al. Semin Arth Rheum. 2015;44(5):556–562.
UK | April 2021 | 114838
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]